Matches in Wikidata for { <http://www.wikidata.org/entity/Q65375640> ?p ?o ?g. }
Showing items 1 to 35 of
35
with 100 items per page.
- Q65375640 description "clinical trial" @default.
- Q65375640 description "ensayu clínicu" @default.
- Q65375640 description "klinisch onderzoek" @default.
- Q65375640 description "клінічне випробування" @default.
- Q65375640 name "A Randomized, Double-Blind, Comparator- and Placebo-Controlled, Multiple-Dose Study to Evaluate the Safety, Tolerability and Efficacy of Three Dose Levels of MSDC-0602 in Type 2 Diabetic Patients" @default.
- Q65375640 name "A Randomized, Double-Blind, Comparator- and Placebo-Controlled, Multiple-Dose Study to Evaluate the Safety, Tolerability and Efficacy of Three Dose Levels of MSDC-0602 in Type 2 Diabetic Patients" @default.
- Q65375640 type Item @default.
- Q65375640 label "A Randomized, Double-Blind, Comparator- and Placebo-Controlled, Multiple-Dose Study to Evaluate the Safety, Tolerability and Efficacy of Three Dose Levels of MSDC-0602 in Type 2 Diabetic Patients" @default.
- Q65375640 label "A Randomized, Double-Blind, Comparator- and Placebo-Controlled, Multiple-Dose Study to Evaluate the Safety, Tolerability and Efficacy of Three Dose Levels of MSDC-0602 in Type 2 Diabetic Patients" @default.
- Q65375640 prefLabel "A Randomized, Double-Blind, Comparator- and Placebo-Controlled, Multiple-Dose Study to Evaluate the Safety, Tolerability and Efficacy of Three Dose Levels of MSDC-0602 in Type 2 Diabetic Patients" @default.
- Q65375640 prefLabel "A Randomized, Double-Blind, Comparator- and Placebo-Controlled, Multiple-Dose Study to Evaluate the Safety, Tolerability and Efficacy of Three Dose Levels of MSDC-0602 in Type 2 Diabetic Patients" @default.
- Q65375640 P1050 Q65375640-67796C4D-E7EB-4ECF-A57E-4A32CCEA0F0C @default.
- Q65375640 P1132 Q65375640-829E4152-7D84-432C-8D7F-D80DA2A191F7 @default.
- Q65375640 P1476 Q65375640-72ACF6F1-30F0-4372-9E02-6796F18928B9 @default.
- Q65375640 P17 Q65375640-B4B049E8-A4B2-4CD3-AABF-B2693E17F664 @default.
- Q65375640 P2899 Q65375640-7A4E50AC-248A-4DE1-A743-98AA7CF01CB0 @default.
- Q65375640 P3098 Q65375640-7A8FEC51-18B9-469E-9E28-3CC0ACB234E5 @default.
- Q65375640 P31 Q65375640-744F750D-A44E-4AF9-847D-571DEBF12551 @default.
- Q65375640 P4135 Q65375640-10E707FA-C018-462A-A7ED-50D9AB944F6D @default.
- Q65375640 P580 Q65375640-47544CD1-1706-4244-9975-1CC0C4F9382F @default.
- Q65375640 P582 Q65375640-F206237A-9ADC-4C31-AC50-CE160FFC1054 @default.
- Q65375640 P6099 Q65375640-80714847-A628-4185-BED1-6F0452E61DCE @default.
- Q65375640 P8363 Q65375640-BE3F71FB-BF57-4037-A754-F3D88DD8A26F @default.
- Q65375640 P1050 Q12206 @default.
- Q65375640 P1132 "+129" @default.
- Q65375640 P1476 "A Phase 2a, Randomized, Double-Blind, Comparator- and Placebo-Controlled, Multiple-Dose Study to Evaluate the Safety, Tolerability and Efficacy of Three Dose Levels of MSCD-0602 in Type 2 Diabetic Patients" @default.
- Q65375640 P17 Q30 @default.
- Q65375640 P2899 "+18" @default.
- Q65375640 P3098 "NCT01280695" @default.
- Q65375640 P31 Q30612 @default.
- Q65375640 P4135 "+75" @default.
- Q65375640 P580 "2011-02-01T00:00:00Z" @default.
- Q65375640 P582 "2011-06-01T00:00:00Z" @default.
- Q65375640 P6099 Q42824440 @default.
- Q65375640 P8363 Q78089383 @default.